Clinical trials: Severe Burn
Burns
Fluid Resuscitation in Patients Suffering From Burns Injury
This clinical study compares two fluid resuscitation treatments in patients suffering from burns injury. The treatments are Volulyte® and Human Serum Albumin (HSA) which will be administered as infusion solutions.
- Trial name
- NCT01689506
- Testing
- Volulyte, Human Serum Albumin
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- Fresenius Kabi
Cancer, Breakthrough Pain
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
The primary objective of the study is to evaluate the efficacy of ACTIQ treatment for the management of breakthrough pain (BTP) compared to placebo treatment in children with cancer and non-cancer pain who are receiving…
- Trial name
- NCT00236041
- Testing
- ACTIQ®
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 38 people
- Sponsor
- Cephalon
Burns
Efficacy and Tolerance of Cellularised LG002 Versus Uncellularised LG002 in the Treatment of Severe Burns Injuries
After severe burn injury, the full-thickness burn areas are excised (in the first week) and then temporarily covered with allograft (cryogenic preserved cadaver skin).
- Trial name
- NCT00366041
- Testing
- Dermal substrate cellularised LG002 (10x10cm), Dermal substrate uncellularised LG002 (10x10 cm)
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- Laboratoires Genévrier
Infections on, Severe Burn Patients
Effect of Early Enteral Tube Feeding Nutrition With an Immune Enhancing Diet in Severe Burn Patients
Compare clinical and biological effects of two enteral tube feeding nutrition formula (immune enhancing diet versus polymeric diet)in severe burn hospitalized patients .
- Trial name
- NCT00561210
- Testing
- Crucial, Sondalis HP
- Where
- 5 sites in France
- Volunteers
- 57 people
- Sponsor
- Société des Produits Nestlé (SPN)
Burns
Evaluation Of Linezolid Pk Profile In Burns Patients
Evaluation of linezolid pk profile in burns patients
- Trial name
- NCT00255996
- Testing
- linezolid
- Where
- 3 sites in France
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Burns
Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns
This is a multi-center, pivotal study to assess the safety and effectiveness of a new method of treating severe burns using NovoSorb® Biodegradable Temporizing Matrix (BTM).
- Trial name
- NCT04090424
- Testing
- NovoSorb BTM, Standard of Care
- Where
- 26 sites in United States, India
- Volunteers
- 150 people
- Sponsor
- PolyNovo Biomaterials Pty Ltd.
Burn Wound
Clinical Efficacy and Safety of Autologous Cultured Keratinocyte Cell on Severe Burn Wood
The efficacy and safety of Autologous cultured keratinocyte cell on severe burn wound.
- Trial name
- keratinocyte (NCT00978705)
- Testing
- Autologous cultured keratinocyte cell
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Biosolution Co., Ltd.
Hypercatabolic Status Related to Severe Burn
Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects
Study of tolerability and efficacy of BVS857 in severe burn subjects over 8 weeks and 15 weeks
- Trial name
- NCT02074995
- Testing
- BVS857
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Barrett's Esophagus, High-grade Dysplasia in Barrett Esophagus
Eradicating Barrett's Esophagus Using Radiofrequency Ablation or a Novel Hybrid Argon Plasma Coagulation Technique
Lay summary: Barrett's Esophagus (BE) involves a change of the esophagus lining (BE epithelium) which in a small proportion of patients could be the starting point for the development of cancer (esophageal adenocarcinoma).
- Conditions
- Barrett's Esophagus, High-grade Dysplasia in Barrett Esophagus, Low Grade Dysplasia in Barrett Esophagus
- Trial name
- BURN (NCT03621319)
- Testing
- Hybrid argon plasma ablation (HAPC), Radiofrequency ablation (RFA)
- Where
- 13 sites in United States
- Volunteers
- 41 people
- Sponsor
- Erbe Elektromedizin GmbH
Pain, Cancer
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
The objective of the study is to monitor the safety (adverse event data) of longer-term use of ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC]) treatment in children with pain associated with cancer, sickle cell disease, or…
- Conditions
- Pain, Cancer, Sickle Cell Anemia, Severe Burns
- Trial name
- NCT00236093
- Testing
- ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])
- Where
- 28 sites in United States, Canada and 1 more
- Sponsor
- Cephalon